Search Results
AZD-9291 50mg 50mg | Purity Not Available
Adooq Bioscience
AZD-9291 is a third-generation EGFR inhibitor, showed promise in preclinical studies and provides hope for patients with advanced lung cancers that have become resistant to existing EGFR inhibitors.
More Information Supplier PageAZD-9291 5mg 5mg | Purity Not Available
Adooq Bioscience
AZD-9291 is a third-generation EGFR inhibitor, showed promise in preclinical studies and provides hope for patients with advanced lung cancers that have become resistant to existing EGFR inhibitors.
More Information Supplier PageAZD-9291 25mg 25mg | Purity Not Available
Adooq Bioscience
AZD-9291 is a third-generation EGFR inhibitor, showed promise in preclinical studies and provides hope for patients with advanced lung cancers that have become resistant to existing EGFR inhibitors.
More Information Supplier PageAZD-9291 10mM * 1mL in DMSO 10mM * 1mL in DMSO | Purity Not Available
Adooq Bioscience
AZD-9291 is a third-generation EGFR inhibitor, showed promise in preclinical studies and provides hope for patients with advanced lung cancers that have become resistant to existing EGFR inhibitors.
More Information Supplier PageAZD-9291 10mg 10mg | Purity Not Available
Adooq Bioscience
AZD-9291 is a third-generation EGFR inhibitor, showed promise in preclinical studies and provides hope for patients with advanced lung cancers that have become resistant to existing EGFR inhibitors.
More Information Supplier PageRolapitant 5mg 5mg | Purity Not Available
Adooq Bioscience
Rolapitant, also known as SCH-619734, is a selective, bioavailable, CNS penetrant neurokinin NK1 receptor antagonist that shows behavioral effects in animals models of emesis.
More Information Supplier PageBI-78D3 10mg 10mg | Purity Not Available
Adooq Bioscience
BI-78D3 is a competitive JNK (c-Jun N-terminal kinases) inhibitor (IC50 = 280 nM) that displays > 100 fold selectivity over p38?? and no activity at mTOR and PI-3K. BI 78D3 inhibits JIP1(JNK interacting protein 1)-JNK binding (IC50 = 500 nM).
More Information Supplier PageBI-78D3 25mg 25mg | Purity Not Available
Adooq Bioscience
BI-78D3 is a competitive JNK (c-Jun N-terminal kinases) inhibitor (IC50 = 280 nM) that displays > 100 fold selectivity over p38?? and no activity at mTOR and PI-3K. BI 78D3 inhibits JIP1(JNK interacting protein 1)-JNK binding (IC50 = 500 nM).
More Information Supplier Page